Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, and By Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 8.47 Billion
CAGR (2026-2031)	6.39%
Fastest Growing Segment	Retail Pharmacies
Largest Market	North America
Market Size (2031)	USD 12.28 Billion

Market Overview

The Global Heart Failure Therapeutics Market will grow from USD 8.47 Billion in 2025 to USD 12.28 Billion by 2031 at a 6.39% CAGR. Heart failure therapeutics encompass a diverse category of pharmaceutical agents, including diuretics and angiotensin converting enzyme inhibitors, designed to improve cardiac efficiency and alleviate clinical symptoms. The primary drivers propelling market growth include the rapidly aging global population and the increasing prevalence of comorbidities such as hypertension and diabetes which predispose individuals to cardiac insufficiency. This rising disease burden creates a substantial demand for advanced treatment options and supports the continuous development of novel pharmacotherapies. According to the Heart Failure Society of America, in 2024, approximately 6.7 million adults in the United States were estimated to be living with heart failure.

A significant challenge impeding the expansion of this market is the high financial cost associated with emerging drug classes and advanced therapeutic regimens. Limited healthcare reimbursement budgets in many developing nations often restrict patient access to these premium medications. Consequently, healthcare providers frequently rely on older and lower cost generic alternatives to manage patient care. This economic constraint hinders the revenue potential for manufacturers of innovative heart failure drugs and slows the overall progression of the global market.

Key Market Drivers

The escalating global prevalence of heart failure and a rapidly aging geriatric population serve as the primary engines for market expansion. As life expectancy increases, the cumulative risk of developing cardiac insufficiency rises, creating a sustained patient base that necessitates long-term management. This demographic shift is compounded by the rising incidence of lifestyle-related comorbidities, which accelerates disease progression and intensifies the need for medical intervention. According to the Heart Failure Society of America, September 2024, in the 'HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics' report, the number of adults living with heart failure in the United States is projected to rise to 11.4 million by 2050. This surge in patient volume directly correlates with an increased urgency for effective therapeutic interventions and drives the scale of market demand.

Advancements in novel pharmacological therapies and drug classes are fundamentally reshaping the treatment landscape. The introduction of innovative agents, such as Angiotensin Receptor-Neprilysin Inhibitors and Sodium-Glucose Cotransporter-2 inhibitors, offers superior clinical outcomes compared to traditional regimens, thereby encouraging widespread clinical adoption. Pharmaceutical companies are capitalizing on these scientific breakthroughs by commercializing high-value therapeutics that command significant market share. For instance, according to Novartis, January 2024, in the 'Annual Report 2023', sales of the heart failure drug Entresto grew by 30% to USD 6.0 billion. Similarly illustrating the commercial impact of these modern therapeutic classes, according to Boehringer Ingelheim, April 2024, in the 'Annual Report 2023', sales of the drug Jardiance reached EUR 7.4 billion.

Download Free Sample Report

Key Market Challenges

The high financial cost associated with emerging drug classes and advanced therapeutic regimens constitutes a primary restraint on the global heart failure therapeutics market. Innovative pharmaceutical agents often carry premium pricing that exceeds the capacity of public health budgets and insurance reimbursement plans, particularly in developing nations. When healthcare systems face these strict financial limitations, providers are frequently compelled to prioritize older, lower-cost generic alternatives over newer, patented medications. This trend directly limits the revenue potential for manufacturers of novel therapies and decelerates the commercial adoption of clinically advanced treatments.

The economic burden placed on healthcare infrastructure further exacerbates this issue, creating a barrier to the widespread entry of high-cost drugs. According to the American Heart Association, in 2024, the total cost of cardiovascular disease in the United States was projected to potentially reach $1.8 trillion by 2050. This magnitude of projected expenditure forces payers to implement rigorous cost-containment measures. Consequently, the market faces sustained pressure as restricted reimbursement policies hamper the ability of patients to access effective but expensive heart failure management solutions.

Key Market Trends

Adoption of GLP-1 Agonists for Obesity-Related Heart Failure is significantly altering the treatment landscape by targeting metabolic comorbidities that exacerbate cardiac insufficiency. This trend signifies a departure from traditional hemodynamic modulation toward therapies that address systemic drivers of disease, particularly in patients with preserved ejection fraction and high body mass index. Pharmaceutical developers are successfully leveraging these agents to mitigate cardiovascular risks in this expanding patient demographic, moving beyond simple weight management to clinical cardiovascular protection. According to Novo Nordisk, March 2024, in the 'Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity' press release, the pivotal SELECT trial demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared to placebo.

Emergence of Gene Therapy and Regenerative Medicine Pipelines focuses on delivering curative interventions for genetically defined cardiomyopathies, moving beyond symptom management to address root molecular causes. This innovative approach is gaining traction with the advancement of viral vector-based delivery systems designed to restore functional protein expression in cardiac tissue. Clinical trials in this sector are producing data that validates the potential for long-term structural improvement and disease reversal in the heart. According to Rocket Pharmaceuticals, November 2024, in the 'Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data' press release, the company reported that its investigational gene therapy for Danon disease resulted in a median 24% reduction in left ventricular mass index at 12 months.

Segmental Insights

The Retail Pharmacies segment is the fastest-growing category in the Global Heart Failure Therapeutics Market, driven by a significant shift toward outpatient disease management. This expansion is largely supported by the increasing availability and prescription of oral medications, which enable patients to administer treatments independently at home. Furthermore, the widespread presence of retail chains offers superior accessibility compared to hospital pharmacies, thereby enhancing medication adherence among the elderly population. As healthcare providers focus on reducing hospital readmission rates, retail pharmacies have become the primary channel for dispensing essential maintenance therapies for chronic heart failure.

Regional Insights

North America holds the leading position in the heart failure therapeutics market, primarily driven by the rising prevalence of cardiovascular conditions and a well-established healthcare infrastructure. The region benefits from the strong presence of major pharmaceutical companies and significant investment in clinical research. Furthermore, supportive regulatory frameworks from the US Food and Drug Administration facilitate the timely approval of new treatments. High healthcare expenditure and comprehensive reimbursement policies also ensure widespread patient access to therapies, solidifying the region's dominance in the global landscape.

Recent Developments

• In November 2024, Eli Lilly and Company presented detailed findings from the Phase III SUMMIT clinical trial, which investigated the safety and efficacy of tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. The results, shared at a major scientific congress, indicated that the treatment reduced the risk of worsening heart failure events and cardiovascular death by 38% compared to placebo. Additionally, patients treated with the drug experienced significant improvements in exercise capacity and substantial weight loss. These data support the potential regulatory filing for tirzepatide as a first-in-class treatment for this specific heart failure population.
• In August 2024, Bayer announced positive topline results from the pivotal Phase III FINEARTS-HF clinical trial, which evaluated the efficacy of Kerendia (finerenone) in patients with heart failure with mildly reduced or preserved ejection fraction. The study successfully met its primary endpoint by demonstrating a statistically significant reduction in the composite risk of cardiovascular death and total heart failure events, including hospitalizations. This breakthrough research highlights the potential of the non-steroidal mineralocorticoid receptor antagonist to improve outcomes for a broad spectrum of heart failure patients, specifically addressing a segment with few approved therapeutic options.
• In May 2024, AstraZeneca expanded its research efforts in the Global Heart Failure Therapeutics Market by selecting a novel heart failure target discovered through its ongoing collaboration with BenevolentAI. This strategic partnership leverages an artificial intelligence-driven drug discovery platform to identify biological targets that have been traditionally difficult to find. The selection of this new target triggered a milestone payment to BenevolentAI and underscores AstraZeneca's commitment to addressing unmet medical needs in heart failure. The collaboration combines the pharmaceutical company's disease-specific expertise with advanced AI capabilities to accelerate the development of next-generation treatments.
• In March 2024, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events, such as cardiovascular death, heart attack, and stroke. This approval applies to adults with established cardiovascular disease who also have obesity or overweight. The decision was based on the SELECT cardiovascular outcomes trial, which demonstrated a statistically significant reduction in these risks. This label expansion marks a pivotal development in the Global Heart Failure Therapeutics Market, offering a dual benefit of weight management and cardiovascular protection for high-risk patients.

Key Market Players

• Bayer AG
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Amgen Inc
• Boehringer Ingelheim GmbH
• Pfizer Inc
• Johnson & Johnson
• Eli Lilly and Company

By Drug Class	By Distribution Channel	By Region
ACE Inhibitors Angiotensin 2 Receptor Blockers Beta Blockers Diuretics Aldosterone Antagonists Inotropes Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Heart Failure Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Heart Failure Therapeutics Market, By Drug Class:

• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Inotropes
• Others

• Heart Failure Therapeutics Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Heart Failure Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE